Seroprotection and Seroconversion Rates for the 3 Poliovirus Types after 1 Dose in Combined Groups 1 and 2 and After 2 Doses in Group 2 (Per-Protocol Population)
| . | . | Seroprotection or Seroconversion Rate, No./Total (%; 95% CI) . | |||||
|---|---|---|---|---|---|---|---|
| . | . | Poliovirus Type 1 . | Poliovirus Type 2 . | Poliovirus Type 3 . | |||
| Rate . | Day . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . |
| Seroprotection | 0 | 93/96 (97; 91.1–99.4) | 47/47 (100; 92.5–100) | 94/96 (98; 92.7–99.7) | 47/47 (100; 92.5–100) | 92/96 (96; 89.7–98.9) | 45/47 (96; 85.5–99.5) |
| 7 | 48/50 (96; 86.3–99.5) | … | 49/50 (98; 89.4–99.9) | … | 49/50 (98; 89.4–99.9) | … | |
| 28 | 88/90 (98; 92.2–99.7) | 45/46 (98; 88.5–99.9) | 90/90 (100; 96.0–100) | 46/46 (100; 92.3–100) | 87/90 (97; 90.6–99.3) | 44/46 (96; 85.2–99.5) | |
| 56 | … | 43/43 (100; 91.8–100) | … | 43/42 (100; 91.8–100) | … | 41/43 (95; 84.2–99.4) | |
| Seroconversiona | 7 | 4/20 (20; 5.7–43.7) | … | 9/24 (38; 18.8–59.4) | … | 2/19 (11; 1.3–33.1) | … |
| 28 | 9/29 (31; 15.3–50.8) | … | 29/41 (71; 54.5–83.9) | … | 3/31 (10; 2.0–25.8) | … | |
| 56 | … | 3/10 (30; 6.7–65.2) | … | 11/17 (65; 38.3–85.8) | … | 1/12 (8; 0.2–38.5) | |
| . | . | Seroprotection or Seroconversion Rate, No./Total (%; 95% CI) . | |||||
|---|---|---|---|---|---|---|---|
| . | . | Poliovirus Type 1 . | Poliovirus Type 2 . | Poliovirus Type 3 . | |||
| Rate . | Day . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . |
| Seroprotection | 0 | 93/96 (97; 91.1–99.4) | 47/47 (100; 92.5–100) | 94/96 (98; 92.7–99.7) | 47/47 (100; 92.5–100) | 92/96 (96; 89.7–98.9) | 45/47 (96; 85.5–99.5) |
| 7 | 48/50 (96; 86.3–99.5) | … | 49/50 (98; 89.4–99.9) | … | 49/50 (98; 89.4–99.9) | … | |
| 28 | 88/90 (98; 92.2–99.7) | 45/46 (98; 88.5–99.9) | 90/90 (100; 96.0–100) | 46/46 (100; 92.3–100) | 87/90 (97; 90.6–99.3) | 44/46 (96; 85.2–99.5) | |
| 56 | … | 43/43 (100; 91.8–100) | … | 43/42 (100; 91.8–100) | … | 41/43 (95; 84.2–99.4) | |
| Seroconversiona | 7 | 4/20 (20; 5.7–43.7) | … | 9/24 (38; 18.8–59.4) | … | 2/19 (11; 1.3–33.1) | … |
| 28 | 9/29 (31; 15.3–50.8) | … | 29/41 (71; 54.5–83.9) | … | 3/31 (10; 2.0–25.8) | … | |
| 56 | … | 3/10 (30; 6.7–65.2) | … | 11/17 (65; 38.3–85.8) | … | 1/12 (8; 0.2–38.5) | |
Abbreviation: CI, confidence interval.
aSeroconversion was calculated only for those whose baseline titer was sufficiently low to allow observation of 4-fold increase without exceeding the upper limit of quantitation (ie, baseline titer ≤8.5 log2.)
Seroprotection and Seroconversion Rates for the 3 Poliovirus Types after 1 Dose in Combined Groups 1 and 2 and After 2 Doses in Group 2 (Per-Protocol Population)
| . | . | Seroprotection or Seroconversion Rate, No./Total (%; 95% CI) . | |||||
|---|---|---|---|---|---|---|---|
| . | . | Poliovirus Type 1 . | Poliovirus Type 2 . | Poliovirus Type 3 . | |||
| Rate . | Day . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . |
| Seroprotection | 0 | 93/96 (97; 91.1–99.4) | 47/47 (100; 92.5–100) | 94/96 (98; 92.7–99.7) | 47/47 (100; 92.5–100) | 92/96 (96; 89.7–98.9) | 45/47 (96; 85.5–99.5) |
| 7 | 48/50 (96; 86.3–99.5) | … | 49/50 (98; 89.4–99.9) | … | 49/50 (98; 89.4–99.9) | … | |
| 28 | 88/90 (98; 92.2–99.7) | 45/46 (98; 88.5–99.9) | 90/90 (100; 96.0–100) | 46/46 (100; 92.3–100) | 87/90 (97; 90.6–99.3) | 44/46 (96; 85.2–99.5) | |
| 56 | … | 43/43 (100; 91.8–100) | … | 43/42 (100; 91.8–100) | … | 41/43 (95; 84.2–99.4) | |
| Seroconversiona | 7 | 4/20 (20; 5.7–43.7) | … | 9/24 (38; 18.8–59.4) | … | 2/19 (11; 1.3–33.1) | … |
| 28 | 9/29 (31; 15.3–50.8) | … | 29/41 (71; 54.5–83.9) | … | 3/31 (10; 2.0–25.8) | … | |
| 56 | … | 3/10 (30; 6.7–65.2) | … | 11/17 (65; 38.3–85.8) | … | 1/12 (8; 0.2–38.5) | |
| . | . | Seroprotection or Seroconversion Rate, No./Total (%; 95% CI) . | |||||
|---|---|---|---|---|---|---|---|
| . | . | Poliovirus Type 1 . | Poliovirus Type 2 . | Poliovirus Type 3 . | |||
| Rate . | Day . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . | Groups 1 and 2 . | Group 2 . |
| Seroprotection | 0 | 93/96 (97; 91.1–99.4) | 47/47 (100; 92.5–100) | 94/96 (98; 92.7–99.7) | 47/47 (100; 92.5–100) | 92/96 (96; 89.7–98.9) | 45/47 (96; 85.5–99.5) |
| 7 | 48/50 (96; 86.3–99.5) | … | 49/50 (98; 89.4–99.9) | … | 49/50 (98; 89.4–99.9) | … | |
| 28 | 88/90 (98; 92.2–99.7) | 45/46 (98; 88.5–99.9) | 90/90 (100; 96.0–100) | 46/46 (100; 92.3–100) | 87/90 (97; 90.6–99.3) | 44/46 (96; 85.2–99.5) | |
| 56 | … | 43/43 (100; 91.8–100) | … | 43/42 (100; 91.8–100) | … | 41/43 (95; 84.2–99.4) | |
| Seroconversiona | 7 | 4/20 (20; 5.7–43.7) | … | 9/24 (38; 18.8–59.4) | … | 2/19 (11; 1.3–33.1) | … |
| 28 | 9/29 (31; 15.3–50.8) | … | 29/41 (71; 54.5–83.9) | … | 3/31 (10; 2.0–25.8) | … | |
| 56 | … | 3/10 (30; 6.7–65.2) | … | 11/17 (65; 38.3–85.8) | … | 1/12 (8; 0.2–38.5) | |
Abbreviation: CI, confidence interval.
aSeroconversion was calculated only for those whose baseline titer was sufficiently low to allow observation of 4-fold increase without exceeding the upper limit of quantitation (ie, baseline titer ≤8.5 log2.)
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
